二环丙胺盐酸盐 | 246257-69-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 二环丙胺盐酸盐
• 英文名称: dicyclopropylamine hydrochloride
• 英文别名: N-cyclopropylcyclopropanamine;hydrochloride
• CAS: 246257-69-2
• 化学式: C₆H₁₁N*ClH
• mdl: MFCD06796385
• 分子量: 133.621
• InChiKey: FUIHNRAZVMHKIS-UHFFFAOYSA-N

物化性质

• 熔点：
  130-131 °C

计算性质

• 辛醇/水分配系数(LogP)：
  0.74
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 海关编码：
  2921300090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  | 室温 |

反应信息

• 作为反应物：
  描述：

  二环丙胺盐酸盐 在 titanium(IV) isopropylate 、 sodium hydroxide 、 四丁基氯化铵 作用下， 以 四氢呋喃 、 乙醚 、 氯仿 、 水 为溶剂， 反应 14.0h， 生成 二环丙胺
  参考文献：
  名称：

  Radical Cations of Trialkylamines:  ESR Spectra and Structures

  摘要：

  Novel syntheses of cyclopropyldiisopropylamine (15), di-tert-butylcyclopropylamine (16), dicyclopropylisopropylamine (17), and tricyclopropylamine (18) are described. Hyperfine data were determined by ESR spectroscopy for the radical cations of these trialkylamines, as well as for those of ethyldiisopropylamine (10), diisopropyl-n-propylamine (11), dicyclohexylethylamine (12), diisopropyl-3-pentylamine (14), and 1-azabicyclo[3.3.3]undecane (manxine; 27). The radical cation of triisopropylamine (13) was reexamined under conditions of improved spectral resolution. Coupling constants of the N-14 nucleus and the beta-protons in the radical cations of 18 trialkylamines provide reliable information about the geometries of these species, which are confirmed by theoretical calculations. With the exception of a few oligocyclic amines, for which flattening is impaired by the rigid molecular framework, all of the radical cations should be planar. Correlation between the observed coupling constants of the beta-protons and the calculated values of the dihedral angle theta, defining the conformation of the alkyl substituent or the azacycloalkane, is verified. Upon oxidation, striking changes occur for those amines that have cyclopropyl substituents, because of the tendency of these groups to assume a perpendicular conformation in the neutral amines and a bisected orientation in the corresponding radical cations.

  DOI：

  10.1021/jo990458n
• 作为产物：
  描述：

  N,N-dicyclopropyl 4-nitrobenzenesulfonamide 在 1-癸硫醇 、 potassium 2-methylbutan-2-olate 、 盐酸 、 potassium phosphate 、 dipotassium hydrogenphosphate 、 三甲基氯硅烷 作用下， 以 四氢呋喃 、 甲苯 、 水 、 异丙醇 为溶剂， 反应 1.92h， 生成 二环丙胺盐酸盐
  参考文献：
  名称：

  Development of a Robust Process for the Preparation of High-Quality Dicyclopropylamine Hydrochloride

  摘要：

  A short and efficient process for the preparation of high-quality dicyclopropylamine HCl salt is described. An oxygen-mediated Chan-Lam coupling of N-cyclopropyl 4-nitrobenzenesulfonamide with cyclopropylboronic acid was followed by an optimized p-nosyl deprotection with 1-decanethiol, providing the title compound in high chemical yield. This process addresses many of the challenges and liabilities inherent in previous synthetic approaches to this challenging molecule. The collection of key safety data enabled implementation of an oxygen-mediated process on-scale and ensured safe operation throughout development, optimization, and processing.

  DOI：

  10.1021/op500031z
• 作为试剂：
  描述：

  sodium 4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxylate 、 二环丙胺盐酸盐 在 二环丙胺盐酸盐 作用下， 以89的产率得到N,N-二环丙基-4-[(1,5-二甲基-1H-吡唑-3-基)氨基]-6-乙基-1,6-二氢-1-甲基-咪唑并[4,5-d]吡咯并[2,3-b]吡啶-7-甲酰胺
  参考文献：
  名称：

  J. Org. Chem. 2015, 80, 6001-6011

  摘要：

  DOI：

文献信息

• [EN] HETEROCYCLIC PROLINAMIDE DERIVATIVES<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES DE PROLINAMIDE
  申请人：INCEPTION 4 INC

  公开号：WO2017222915A1

  公开（公告）日：2017-12-28

  This invention is directed to novel heterocyclic prolinamide derivatives of Formula (I), and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry-AMD, wet-AMD, and geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells, comprising: administration of a therapeutically effective amount of compound of the invention. The compounds of the invention are inhibitors of HTRAl. Thus, the compounds of the invention are useful in the prevention and treatment of a wide range of diseases mediated (in whole or in part) by HTRAl. The compounds of the invention are also useful for inhibiting HTRAl protease activity in an eye or locus of an arthritis or related condition.

  这项发明涉及一种新颖的Formula (I)异环脯氨酰胺衍生物，以及在预防（例如，延缓或减少发展风险）和治疗（例如，控制、缓解或减缓进展）与眼睛相关的年龄相关性黄斑变性（AMD）和相关疾病中有用的药用盐、溶剂化合物、盐的溶剂化合物和其前药。这些疾病包括干性AMD、湿性AMD、地理性萎缩、糖尿病视网膜病变、早产儿视网膜病变、多发性脉络膜血管病变以及视网膜或光感受细胞的退化。本公开的发明还涉及预防、减缓进展和治疗干性AMD、湿性AMD、地理性萎缩、糖尿病视网膜病变、早产儿视网膜病变、多发性脉络膜血管病变以及视网膜或光感受细胞的退化的方法，包括：给予所述发明化合物的治疗有效量。本发明的化合物是HTRAl的抑制剂。因此，本发明的化合物在预防和治疗一系列（全部或部分）由HTRAl介导的疾病中有用。本发明的化合物还可用于抑制眼睛或关节炎或相关疾病部位中的HTRAl蛋白酶活性。
• [EN] COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS<br/>[FR] ASSOCIATIONS D'INHIBITEURS DU VIRUS DE L'HÉPATITE C
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015005901A1

  公开（公告）日：2015-01-15

  The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

  本公开涉及抗病毒化合物，更具体地涉及能够抑制由丙型肝炎病毒（HCV）编码的NS5A蛋白功能的化合物组合，包括这种组合的组合物，以及抑制NS5A蛋白功能的方法。
• [EN] HETEROAROMATIC DERIVATIVES AS NIK INHIBITORS<br/>[FR] DÉRIVÉS HÉTÉROAROMATIQUES EN TANT QU'INHIBITEURS DE NIK
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2018002217A1

  公开（公告）日：2018-01-04

  The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-κB-inducing kinase (NIK - also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.

  本发明涉及对哺乳动物疗法和/或预防有用的药物，特别是对NF-κB诱导激酶（NIK - 也称为MAP3K14）的抑制剂，用于治疗癌症、炎症性疾病、代谢性疾病和自身免疫性疾病。该发明还涉及包含这些化合物的药物组合物，以及利用这些化合物或药物组合物预防或治疗癌症、炎症性疾病、包括肥胖和糖尿病在内的代谢性疾病以及自身免疫性疾病。
• [EN] BENZAMIDE COMPOUNDS AND THEIR USE AS HERBICIDES II<br/>[FR] COMPOSÉS DE BENZAMIDE ET LEUR UTILISATION EN TANT QU'HERBICIDES II
  申请人：BASF SE

  公开号：WO2018219936A1

  公开（公告）日：2018-12-06

  The invention relates to benzamides of formula (I), wherein Q is Q1 or Q2 or Q3 or Q4, and their use as herbicides. In said formula (I), R2 is R2cR2dNC(O)NR2n-Z2, R5 is hydrogen, R1, R3, R4 and R6 represent groups such as hydrogen, halogen or organic groups such as alkyl or phenyl.The invention further refers to a composition comprising such compound and to the use thereof for controlling unwanted vegetation.

  该发明涉及式(I)的苯甲酰胺，其中Q是Q1或Q2或Q3或Q4，并且它们作为除草剂的用途。在所述的式(I)中，R2是R2cR2dNC(O)NR2n-Z2，R5是氢，R1、R3、R4和R6代表氢、卤素或有机基团，如烷基或苯基。该发明还涉及包含这种化合物的组合物以及将其用于控制不受欢迎的植被的用途。
• [EN] FUSED PYRIDINES WHICH ACT AS INHIBITORS OF H-PGDS<br/>[FR] PYRIDINES FUSIONNÉES AGISSANT EN TANT QU'INHIBITEURS DE H-PGDS
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2019116256A1

  公开（公告）日：2019-06-20

  A compound of formula (I) wherein R1, R2, R3, R4 χ γ anc| A are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  根据本发明的化合物公式(I)，其中R1，R2，R3，R4，χ，γ和A的定义如所述。本发明的化合物是造血前列腺素D合酶（H-PGDS）的抑制剂，可用于治疗杜氏肌营养不良症。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步涉及使用本发明的化合物或包含本发明化合物的药物组合物来抑制H-PGDS活性和治疗与之相关的疾病的方法。